PK-Biomarker-Safety modelling aids choice of recommended Phase II dose and schedule for AZD6738 (ATR inhibitor)Alienor Berges,S. Y. Amy Cheung,Andrew J. Pierce,Emma Dean,Brunella Felicetti,Nathan Standifer,Simon Smith,James Yates,Alan Lau,Christine Stephens,Matthew Krebs,Kevin Harrington,Simon J. HollingsworthCANCER RESEARCH(2018)引用 8|浏览26暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要